The Market research collection of Report Ocean has recently included the “Saudi Arabia Immunodiagnostic Market” Size, Scope, and Forecast 2024-2032 report. This report, prepared by industry experts ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.

The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. The authorisation by the agency marks the first time a ...

(RTTNews) - Revvity (RVTY) received 510(k) clearance from FDA for EUROIMMUN's automated chemiluminescence-based immunoassay test for free testosterone. The company noted that this is the only FDA ...

Revvity, Inc. , today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free ...

"The updated guideline includes numerous new, important recommendations that will enhance the ability of urologists to provide optimal, state-of-the-art care for infertile males,” says Robert E.

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis, and ...